Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haloperidol for Outpatient Cannabinoid Hyperemesis Syndrome
NCT07726069Phase 1Not yet recruiting
- Sponsor
- University of Illinois Chicago
- Start
- Nov 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of haloperidol in Cannabinoid hyperemesis syndrome (CHS), sponsored by University of Illinois Chicago. Primary endpoint: Rate of return to the emergency department at 1 month. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
haloperidol
03
Conditions
Cannabinoid hyperemesis syndrome (CHS)
Beyond the preview
Go deeper on NCT07726069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726069.